Xigris worked, so why did Lilly withdraw the drug?
This article was originally published in Scrip
Executive Summary
The clinical trial that caused Eli Lilly abruptly to withdraw its septic shock treatment Xigris (drotrecogin alfa [activated]) from all markets in October 2011 (scripintelligence.com, 27 October 2011) may have been flawed, or at least atypical of clinical practice, according to a recent meta-analysis of Xigris studies.